DUB

IU1-47 是一种特异性 USP14抑制剂，IC50为 0.6 μM。它诱导培养的神经元中 tau 蛋白降解。它抑制 IsoT/USP5， IC50为 20 μM。

GRL0617 is a selective and competitive SARS-CoVPLpro and deubiquitinase noncovalent inhibitor(IC50 : 0.6 μM, Ki : 0.49 μM).

C527 is a is a pan DUB enzyme inhibitor. Which has a high potency for the USP1/UAF1 complex (IC50=0.88 μM).

HBX 19818 is a specific ubiquitin-specific protease 7 (USP7) inhibitor (IC50: 28.1 μM).

MF-094 is a selective USP30 inhibitor with IC50 of 0.12 μM. MF-094 can increase protein ubiquitination and accelerate mitophagy.Cost-effective and quality-assured.

USP7-IN-10 hydrochloride, also known as compound 1, is a potent inhibitor of the enzyme ubiquitin-specific protease 7 (USP7), exhibiting an IC50 value of 13.39

Ga-CY03 (compound) is a FAP-tracing molecule designed based on the FAP inhibitor QI-18 and labeled with [Ga].

(R)-CMPD-39 is the R-enantiomer of CMPD-39. CMPD-39 acts as a selective non-covalent inhibitor of the ubiquitin-specific protease USP30 with an IC50 of approximately 20 nM and demonstrates high selectivity for other DUB family members at concentrations ranging from 1-100 μM. By inhibiting USP30's deubiquitination activity, CMPD-39 enhances the ubiquitination of mitochondrial proteins TOMM20 and SYNJ2BP and promotes the accumulation of phosphorylated ubiquitin. This process accelerates both mitophagy and pexophagy. Additionally, CMPD-39 significantly restores impaired mitochondrial function in dopaminergic neurons derived from Parkinson’s disease patients.

USP30-IN-20 is an orally active USP30 inhibitor with a Kd of 1.61 μM and an IC50 of 12.8 μM. It induces ferroptosis by promoting the ubiquitination-mediated degradation of GPX4. This compound inhibits the proliferation, migration, and invasion of prostate cancer cells and induces G0/G1 phase arrest while increasing ROS levels. In a mouse xenograft model with PC3 cells, USP30-IN-20 demonstrates significant antitumor activity. It is applicable for advanced prostate cancer research.

UBD1031 exhibits strong affinity for the ubiquitin-binding domain (UBD) of USP16, with a dissociation constant (KD) of 48 nM. It inhibits the interaction between USP16 and ISG15, displaying an effective concentration (EC50) of 1.7 nM. UBD1031 can serve as a chemical probe for investigating USP16 UBD.

Subquinocin is a CYLD inhibitor that suppresses deubiquitinating enzymes (DUB) of the USP family. By inhibiting CYLD, Subquinocin enhances the activation of the NF-κB and IFN pathways. Additionally, Subquinocin facilitates the activation of IRF3 and/or IRF7 in the RIG-I-mediated interferon pathway.

FT206 is a carboxamide inhibitor of ubiquitin-specific protease[1].

Q14 is a polypeptide derived from the transmembrane (TM) domain of USP30 (ubiquitin specific peptidase30) and is capable of inhibiting the deubiquitination activity of USP30 (IC₅₀=57.2 nM). By hindering the interaction between USP30’s transmembrane and catalytic domains, it lowers USP30 activity. The Q14 polypeptide contains an LC3 interaction region (LIR) motif, enabling it to bind with LC3, thereby accelerating autophagosome formation and promoting mitophagy. Q14 is applicable in the study of neurodegenerative diseases, mitochondrial quality control, and cellular metabolism.

MS7131 is a DUBTAC inhibitor that recruits USP1. It effectively reduces histone H3 lysine 27 trimethylation and significantly inhibits the proliferation and colony-forming ability of cancer cells.

A unique collection of xnum ubiquitination related small chemicals can be used for high throughput and high content screening；

JAMM inhibitor 2 targets thrombin, Rpn11, MMP2 with IC50s 10, 46, 89 μM, aids cancer research.

PROTACUSP7 Degrader-1 (Compound 40) is a PROTAC degrader specifically targeting ubiquitin-specific protease 7 (USP7) with a DC50 of 25 nM. It is utilized in cancer research, including studies on acute myeloid leukemia.

BAY-728 serves as a negative control for BAY-805, a potent and selective inhibitor of USP21 [1].

PROTACUSP7 Degrader-2 (Compound D16) is a potent and selective USP7 PROTAC degrader with a DC₅₀ of 1.91 μM (in TE-12 cells). It inhibits the migration of upper gastrointestinal (UGI) cancer cells while exhibiting weak antiproliferative activity. This compound is utilized for research on metastatic UGI cancer.

G13KS: UCHL1 ligand, deubiquitinase inhibitor; reduces monoubiquitin in glioblastoma cells.